Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR441566 + methotrexate
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SAR441566 + methotrexate is an investigational combination therapy studied in adults with moderate-to-severe rheumatoid arthritis who are not adequately controlled on methotrexate and are naive to biologic/targeted synthetic DMARDs. SAR441566 is a novel oral small molecule being developed as an add-on to background methotrexate therapy to improve disease outcomes in rheumatoid arthritis. Methotrexate is an established disease-modifying antirheumatic drug (DMARD) with anti-inflammatory and immunosuppressive effects, widely used as a first-line agent in rheumatoid arthritis[1][2][4][6].
- Other names
- MTXMethotrexate
02
Targets
DHFR (Dihydrofolate reductase)NADH:ubiquinone oxidoreductase subunit family
Beyond the preview
Go deeper on SAR441566 + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR441566 + methotrexate.